In addition, given that trastuzumab and pertuzumab results in a synergistic effect on increased breast cancer cell death8 and that intratumoral heterogeneity of HER2 gene expression exists,28 treatment with dual‐agent HER2‐targeted therapy may result in increased clonal selection for HER‐negative tumor cells. This evidence concerns the gene ERBB2 and neoplasm.